Ashkan Shoamanesh: FDA Grants Asundexian A Priority Review for Secondary Stroke Prevention
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”Excellent news for patients with ischemic stroke and high-risk TIA: the U.S. FDA has granted Priority Review to asundexian for secondary stroke prevention based on the results of the OCEANIC-STROKE trial.
This marks an important step toward the potential rapid availability of a novel treatment strategy aimed at reducing recurrent ischemic events without increasing major bleeding risk – a long-standing unmet need in stroke prevention.
Very hopeful that other global regulatory agencies will follow suit so that patients worldwide may benefit from timely access to this therapy.”
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 19, 2026, 22:24Erik Nelson: Low Iron Can Raise A1c without Changing Blood Sugar
-
Nov 19, 2026, 22:23Erwin Loh: Daily Iron Supplementation Reduces Iron-Deficiency Anaemia in Children and Adolescents
-
Nov 19, 2026, 22:22Afifah Sardar: Why Can a Simple Painkiller like Aspirin Make You Bleed More?
-
Nov 19, 2026, 22:16Jonathan Penm: Perioperative Anticoagulation Management and Antithrombotic Stewardship Across 31 Countries
-
Nov 19, 2026, 22:15Salomao V.: Innovation in Hemophilia A Is Also About How Patients Receive Their Treatment
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing